Medical Care
Global Cancer Companion Diagnostic Market Research Report 2025
- May 12, 25
- ID: 235179
- Pages: 77
- Figures: 72
- Views: 28
The global market for Cancer Companion Diagnostic was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Companion diagnostic (CD) is an in vitro diagnostic technology that can provide information about a patient"s therapeutic response to a specific therapeutic drug, helping to identify patient groups who can benefit from a certain therapeutic product, thereby improving treatment prognosis. and reduce health care costs. Additionally, companion diagnostics can help identify patient populations most likely to respond to therapeutic agents. The companion diagnostics market is still in its early stages.
The number of cancer patients is gradually increasing, drug accessibility is improving, and the research and development of targeted drugs and immunotherapy continue to increase. This is the main trend of drug development in the next ten years.
This report aims to provide a comprehensive presentation of the global market for Cancer Companion Diagnostic, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cancer Companion Diagnostic.
The Cancer Companion Diagnostic market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Cancer Companion Diagnostic market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Cancer Companion Diagnostic companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
AmoyDx
Novogene
Illumina
Roche
Agilent
Abbott
Thermo Fisher
Qiagen
Guardant Health
Segment by Type
Polymerase Chain Reaction (PCR)
“Next Generation” Sequencing (NGS)
Fluorescence In Situ Hybridization (FISH)
Immunohistochemistry (IHC)
Segment by Application
Lung Cancer
Colorectal Cancer
Breast Cancer
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Cancer Companion Diagnostic company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Companion diagnostic (CD) is an in vitro diagnostic technology that can provide information about a patient"s therapeutic response to a specific therapeutic drug, helping to identify patient groups who can benefit from a certain therapeutic product, thereby improving treatment prognosis. and reduce health care costs. Additionally, companion diagnostics can help identify patient populations most likely to respond to therapeutic agents. The companion diagnostics market is still in its early stages.
The number of cancer patients is gradually increasing, drug accessibility is improving, and the research and development of targeted drugs and immunotherapy continue to increase. This is the main trend of drug development in the next ten years.
This report aims to provide a comprehensive presentation of the global market for Cancer Companion Diagnostic, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cancer Companion Diagnostic.
The Cancer Companion Diagnostic market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Cancer Companion Diagnostic market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Cancer Companion Diagnostic companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
AmoyDx
Novogene
Illumina
Roche
Agilent
Abbott
Thermo Fisher
Qiagen
Guardant Health
Segment by Type
Polymerase Chain Reaction (PCR)
“Next Generation” Sequencing (NGS)
Fluorescence In Situ Hybridization (FISH)
Immunohistochemistry (IHC)
Segment by Application
Lung Cancer
Colorectal Cancer
Breast Cancer
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Cancer Companion Diagnostic company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Cancer Companion Diagnostic Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Polymerase Chain Reaction (PCR)
1.2.3 “Next Generation” Sequencing (NGS)
1.2.4 Fluorescence In Situ Hybridization (FISH)
1.2.5 Immunohistochemistry (IHC)
1.3 Market by Application
1.3.1 Global Cancer Companion Diagnostic Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Lung Cancer
1.3.3 Colorectal Cancer
1.3.4 Breast Cancer
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Cancer Companion Diagnostic Market Perspective (2020-2031)
2.2 Global Cancer Companion Diagnostic Growth Trends by Region
2.2.1 Global Cancer Companion Diagnostic Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Cancer Companion Diagnostic Historic Market Size by Region (2020-2025)
2.2.3 Cancer Companion Diagnostic Forecasted Market Size by Region (2026-2031)
2.3 Cancer Companion Diagnostic Market Dynamics
2.3.1 Cancer Companion Diagnostic Industry Trends
2.3.2 Cancer Companion Diagnostic Market Drivers
2.3.3 Cancer Companion Diagnostic Market Challenges
2.3.4 Cancer Companion Diagnostic Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Cancer Companion Diagnostic Players by Revenue
3.1.1 Global Top Cancer Companion Diagnostic Players by Revenue (2020-2025)
3.1.2 Global Cancer Companion Diagnostic Revenue Market Share by Players (2020-2025)
3.2 Global Cancer Companion Diagnostic Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Cancer Companion Diagnostic Revenue
3.4 Global Cancer Companion Diagnostic Market Concentration Ratio
3.4.1 Global Cancer Companion Diagnostic Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Cancer Companion Diagnostic Revenue in 2024
3.5 Global Key Players of Cancer Companion Diagnostic Head office and Area Served
3.6 Global Key Players of Cancer Companion Diagnostic, Product and Application
3.7 Global Key Players of Cancer Companion Diagnostic, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Cancer Companion Diagnostic Breakdown Data by Type
4.1 Global Cancer Companion Diagnostic Historic Market Size by Type (2020-2025)
4.2 Global Cancer Companion Diagnostic Forecasted Market Size by Type (2026-2031)
5 Cancer Companion Diagnostic Breakdown Data by Application
5.1 Global Cancer Companion Diagnostic Historic Market Size by Application (2020-2025)
5.2 Global Cancer Companion Diagnostic Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Cancer Companion Diagnostic Market Size (2020-2031)
6.2 North America Cancer Companion Diagnostic Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Cancer Companion Diagnostic Market Size by Country (2020-2025)
6.4 North America Cancer Companion Diagnostic Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Cancer Companion Diagnostic Market Size (2020-2031)
7.2 Europe Cancer Companion Diagnostic Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Cancer Companion Diagnostic Market Size by Country (2020-2025)
7.4 Europe Cancer Companion Diagnostic Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Cancer Companion Diagnostic Market Size (2020-2031)
8.2 Asia-Pacific Cancer Companion Diagnostic Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Cancer Companion Diagnostic Market Size by Region (2020-2025)
8.4 Asia-Pacific Cancer Companion Diagnostic Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Cancer Companion Diagnostic Market Size (2020-2031)
9.2 Latin America Cancer Companion Diagnostic Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Cancer Companion Diagnostic Market Size by Country (2020-2025)
9.4 Latin America Cancer Companion Diagnostic Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Cancer Companion Diagnostic Market Size (2020-2031)
10.2 Middle East & Africa Cancer Companion Diagnostic Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Cancer Companion Diagnostic Market Size by Country (2020-2025)
10.4 Middle East & Africa Cancer Companion Diagnostic Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 AmoyDx
11.1.1 AmoyDx Company Details
11.1.2 AmoyDx Business Overview
11.1.3 AmoyDx Cancer Companion Diagnostic Introduction
11.1.4 AmoyDx Revenue in Cancer Companion Diagnostic Business (2020-2025)
11.1.5 AmoyDx Recent Development
11.2 Novogene
11.2.1 Novogene Company Details
11.2.2 Novogene Business Overview
11.2.3 Novogene Cancer Companion Diagnostic Introduction
11.2.4 Novogene Revenue in Cancer Companion Diagnostic Business (2020-2025)
11.2.5 Novogene Recent Development
11.3 Illumina
11.3.1 Illumina Company Details
11.3.2 Illumina Business Overview
11.3.3 Illumina Cancer Companion Diagnostic Introduction
11.3.4 Illumina Revenue in Cancer Companion Diagnostic Business (2020-2025)
11.3.5 Illumina Recent Development
11.4 Roche
11.4.1 Roche Company Details
11.4.2 Roche Business Overview
11.4.3 Roche Cancer Companion Diagnostic Introduction
11.4.4 Roche Revenue in Cancer Companion Diagnostic Business (2020-2025)
11.4.5 Roche Recent Development
11.5 Agilent
11.5.1 Agilent Company Details
11.5.2 Agilent Business Overview
11.5.3 Agilent Cancer Companion Diagnostic Introduction
11.5.4 Agilent Revenue in Cancer Companion Diagnostic Business (2020-2025)
11.5.5 Agilent Recent Development
11.6 Abbott
11.6.1 Abbott Company Details
11.6.2 Abbott Business Overview
11.6.3 Abbott Cancer Companion Diagnostic Introduction
11.6.4 Abbott Revenue in Cancer Companion Diagnostic Business (2020-2025)
11.6.5 Abbott Recent Development
11.7 Thermo Fisher
11.7.1 Thermo Fisher Company Details
11.7.2 Thermo Fisher Business Overview
11.7.3 Thermo Fisher Cancer Companion Diagnostic Introduction
11.7.4 Thermo Fisher Revenue in Cancer Companion Diagnostic Business (2020-2025)
11.7.5 Thermo Fisher Recent Development
11.8 Qiagen
11.8.1 Qiagen Company Details
11.8.2 Qiagen Business Overview
11.8.3 Qiagen Cancer Companion Diagnostic Introduction
11.8.4 Qiagen Revenue in Cancer Companion Diagnostic Business (2020-2025)
11.8.5 Qiagen Recent Development
11.9 Guardant Health
11.9.1 Guardant Health Company Details
11.9.2 Guardant Health Business Overview
11.9.3 Guardant Health Cancer Companion Diagnostic Introduction
11.9.4 Guardant Health Revenue in Cancer Companion Diagnostic Business (2020-2025)
11.9.5 Guardant Health Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Cancer Companion Diagnostic Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Polymerase Chain Reaction (PCR)
1.2.3 “Next Generation” Sequencing (NGS)
1.2.4 Fluorescence In Situ Hybridization (FISH)
1.2.5 Immunohistochemistry (IHC)
1.3 Market by Application
1.3.1 Global Cancer Companion Diagnostic Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Lung Cancer
1.3.3 Colorectal Cancer
1.3.4 Breast Cancer
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Cancer Companion Diagnostic Market Perspective (2020-2031)
2.2 Global Cancer Companion Diagnostic Growth Trends by Region
2.2.1 Global Cancer Companion Diagnostic Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Cancer Companion Diagnostic Historic Market Size by Region (2020-2025)
2.2.3 Cancer Companion Diagnostic Forecasted Market Size by Region (2026-2031)
2.3 Cancer Companion Diagnostic Market Dynamics
2.3.1 Cancer Companion Diagnostic Industry Trends
2.3.2 Cancer Companion Diagnostic Market Drivers
2.3.3 Cancer Companion Diagnostic Market Challenges
2.3.4 Cancer Companion Diagnostic Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Cancer Companion Diagnostic Players by Revenue
3.1.1 Global Top Cancer Companion Diagnostic Players by Revenue (2020-2025)
3.1.2 Global Cancer Companion Diagnostic Revenue Market Share by Players (2020-2025)
3.2 Global Cancer Companion Diagnostic Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Cancer Companion Diagnostic Revenue
3.4 Global Cancer Companion Diagnostic Market Concentration Ratio
3.4.1 Global Cancer Companion Diagnostic Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Cancer Companion Diagnostic Revenue in 2024
3.5 Global Key Players of Cancer Companion Diagnostic Head office and Area Served
3.6 Global Key Players of Cancer Companion Diagnostic, Product and Application
3.7 Global Key Players of Cancer Companion Diagnostic, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Cancer Companion Diagnostic Breakdown Data by Type
4.1 Global Cancer Companion Diagnostic Historic Market Size by Type (2020-2025)
4.2 Global Cancer Companion Diagnostic Forecasted Market Size by Type (2026-2031)
5 Cancer Companion Diagnostic Breakdown Data by Application
5.1 Global Cancer Companion Diagnostic Historic Market Size by Application (2020-2025)
5.2 Global Cancer Companion Diagnostic Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Cancer Companion Diagnostic Market Size (2020-2031)
6.2 North America Cancer Companion Diagnostic Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Cancer Companion Diagnostic Market Size by Country (2020-2025)
6.4 North America Cancer Companion Diagnostic Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Cancer Companion Diagnostic Market Size (2020-2031)
7.2 Europe Cancer Companion Diagnostic Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Cancer Companion Diagnostic Market Size by Country (2020-2025)
7.4 Europe Cancer Companion Diagnostic Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Cancer Companion Diagnostic Market Size (2020-2031)
8.2 Asia-Pacific Cancer Companion Diagnostic Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Cancer Companion Diagnostic Market Size by Region (2020-2025)
8.4 Asia-Pacific Cancer Companion Diagnostic Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Cancer Companion Diagnostic Market Size (2020-2031)
9.2 Latin America Cancer Companion Diagnostic Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Cancer Companion Diagnostic Market Size by Country (2020-2025)
9.4 Latin America Cancer Companion Diagnostic Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Cancer Companion Diagnostic Market Size (2020-2031)
10.2 Middle East & Africa Cancer Companion Diagnostic Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Cancer Companion Diagnostic Market Size by Country (2020-2025)
10.4 Middle East & Africa Cancer Companion Diagnostic Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 AmoyDx
11.1.1 AmoyDx Company Details
11.1.2 AmoyDx Business Overview
11.1.3 AmoyDx Cancer Companion Diagnostic Introduction
11.1.4 AmoyDx Revenue in Cancer Companion Diagnostic Business (2020-2025)
11.1.5 AmoyDx Recent Development
11.2 Novogene
11.2.1 Novogene Company Details
11.2.2 Novogene Business Overview
11.2.3 Novogene Cancer Companion Diagnostic Introduction
11.2.4 Novogene Revenue in Cancer Companion Diagnostic Business (2020-2025)
11.2.5 Novogene Recent Development
11.3 Illumina
11.3.1 Illumina Company Details
11.3.2 Illumina Business Overview
11.3.3 Illumina Cancer Companion Diagnostic Introduction
11.3.4 Illumina Revenue in Cancer Companion Diagnostic Business (2020-2025)
11.3.5 Illumina Recent Development
11.4 Roche
11.4.1 Roche Company Details
11.4.2 Roche Business Overview
11.4.3 Roche Cancer Companion Diagnostic Introduction
11.4.4 Roche Revenue in Cancer Companion Diagnostic Business (2020-2025)
11.4.5 Roche Recent Development
11.5 Agilent
11.5.1 Agilent Company Details
11.5.2 Agilent Business Overview
11.5.3 Agilent Cancer Companion Diagnostic Introduction
11.5.4 Agilent Revenue in Cancer Companion Diagnostic Business (2020-2025)
11.5.5 Agilent Recent Development
11.6 Abbott
11.6.1 Abbott Company Details
11.6.2 Abbott Business Overview
11.6.3 Abbott Cancer Companion Diagnostic Introduction
11.6.4 Abbott Revenue in Cancer Companion Diagnostic Business (2020-2025)
11.6.5 Abbott Recent Development
11.7 Thermo Fisher
11.7.1 Thermo Fisher Company Details
11.7.2 Thermo Fisher Business Overview
11.7.3 Thermo Fisher Cancer Companion Diagnostic Introduction
11.7.4 Thermo Fisher Revenue in Cancer Companion Diagnostic Business (2020-2025)
11.7.5 Thermo Fisher Recent Development
11.8 Qiagen
11.8.1 Qiagen Company Details
11.8.2 Qiagen Business Overview
11.8.3 Qiagen Cancer Companion Diagnostic Introduction
11.8.4 Qiagen Revenue in Cancer Companion Diagnostic Business (2020-2025)
11.8.5 Qiagen Recent Development
11.9 Guardant Health
11.9.1 Guardant Health Company Details
11.9.2 Guardant Health Business Overview
11.9.3 Guardant Health Cancer Companion Diagnostic Introduction
11.9.4 Guardant Health Revenue in Cancer Companion Diagnostic Business (2020-2025)
11.9.5 Guardant Health Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Cancer Companion Diagnostic Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Polymerase Chain Reaction (PCR)
Table 3. Key Players of “Next Generation” Sequencing (NGS)
Table 4. Key Players of Fluorescence In Situ Hybridization (FISH)
Table 5. Key Players of Immunohistochemistry (IHC)
Table 6. Global Cancer Companion Diagnostic Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 7. Global Cancer Companion Diagnostic Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 8. Global Cancer Companion Diagnostic Market Size by Region (2020-2025) & (US$ Million)
Table 9. Global Cancer Companion Diagnostic Market Share by Region (2020-2025)
Table 10. Global Cancer Companion Diagnostic Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 11. Global Cancer Companion Diagnostic Market Share by Region (2026-2031)
Table 12. Cancer Companion Diagnostic Market Trends
Table 13. Cancer Companion Diagnostic Market Drivers
Table 14. Cancer Companion Diagnostic Market Challenges
Table 15. Cancer Companion Diagnostic Market Restraints
Table 16. Global Cancer Companion Diagnostic Revenue by Players (2020-2025) & (US$ Million)
Table 17. Global Cancer Companion Diagnostic Market Share by Players (2020-2025)
Table 18. Global Top Cancer Companion Diagnostic Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cancer Companion Diagnostic as of 2024)
Table 19. Ranking of Global Top Cancer Companion Diagnostic Companies by Revenue (US$ Million) in 2024
Table 20. Global 5 Largest Players Market Share by Cancer Companion Diagnostic Revenue (CR5 and HHI) & (2020-2025)
Table 21. Global Key Players of Cancer Companion Diagnostic, Headquarters and Area Served
Table 22. Global Key Players of Cancer Companion Diagnostic, Product and Application
Table 23. Global Key Players of Cancer Companion Diagnostic, Date of Enter into This Industry
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Cancer Companion Diagnostic Market Size by Type (2020-2025) & (US$ Million)
Table 26. Global Cancer Companion Diagnostic Revenue Market Share by Type (2020-2025)
Table 27. Global Cancer Companion Diagnostic Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 28. Global Cancer Companion Diagnostic Revenue Market Share by Type (2026-2031)
Table 29. Global Cancer Companion Diagnostic Market Size by Application (2020-2025) & (US$ Million)
Table 30. Global Cancer Companion Diagnostic Revenue Market Share by Application (2020-2025)
Table 31. Global Cancer Companion Diagnostic Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 32. Global Cancer Companion Diagnostic Revenue Market Share by Application (2026-2031)
Table 33. North America Cancer Companion Diagnostic Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 34. North America Cancer Companion Diagnostic Market Size by Country (2020-2025) & (US$ Million)
Table 35. North America Cancer Companion Diagnostic Market Size by Country (2026-2031) & (US$ Million)
Table 36. Europe Cancer Companion Diagnostic Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 37. Europe Cancer Companion Diagnostic Market Size by Country (2020-2025) & (US$ Million)
Table 38. Europe Cancer Companion Diagnostic Market Size by Country (2026-2031) & (US$ Million)
Table 39. Asia-Pacific Cancer Companion Diagnostic Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 40. Asia-Pacific Cancer Companion Diagnostic Market Size by Region (2020-2025) & (US$ Million)
Table 41. Asia-Pacific Cancer Companion Diagnostic Market Size by Region (2026-2031) & (US$ Million)
Table 42. Latin America Cancer Companion Diagnostic Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 43. Latin America Cancer Companion Diagnostic Market Size by Country (2020-2025) & (US$ Million)
Table 44. Latin America Cancer Companion Diagnostic Market Size by Country (2026-2031) & (US$ Million)
Table 45. Middle East & Africa Cancer Companion Diagnostic Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 46. Middle East & Africa Cancer Companion Diagnostic Market Size by Country (2020-2025) & (US$ Million)
Table 47. Middle East & Africa Cancer Companion Diagnostic Market Size by Country (2026-2031) & (US$ Million)
Table 48. AmoyDx Company Details
Table 49. AmoyDx Business Overview
Table 50. AmoyDx Cancer Companion Diagnostic Product
Table 51. AmoyDx Revenue in Cancer Companion Diagnostic Business (2020-2025) & (US$ Million)
Table 52. AmoyDx Recent Development
Table 53. Novogene Company Details
Table 54. Novogene Business Overview
Table 55. Novogene Cancer Companion Diagnostic Product
Table 56. Novogene Revenue in Cancer Companion Diagnostic Business (2020-2025) & (US$ Million)
Table 57. Novogene Recent Development
Table 58. Illumina Company Details
Table 59. Illumina Business Overview
Table 60. Illumina Cancer Companion Diagnostic Product
Table 61. Illumina Revenue in Cancer Companion Diagnostic Business (2020-2025) & (US$ Million)
Table 62. Illumina Recent Development
Table 63. Roche Company Details
Table 64. Roche Business Overview
Table 65. Roche Cancer Companion Diagnostic Product
Table 66. Roche Revenue in Cancer Companion Diagnostic Business (2020-2025) & (US$ Million)
Table 67. Roche Recent Development
Table 68. Agilent Company Details
Table 69. Agilent Business Overview
Table 70. Agilent Cancer Companion Diagnostic Product
Table 71. Agilent Revenue in Cancer Companion Diagnostic Business (2020-2025) & (US$ Million)
Table 72. Agilent Recent Development
Table 73. Abbott Company Details
Table 74. Abbott Business Overview
Table 75. Abbott Cancer Companion Diagnostic Product
Table 76. Abbott Revenue in Cancer Companion Diagnostic Business (2020-2025) & (US$ Million)
Table 77. Abbott Recent Development
Table 78. Thermo Fisher Company Details
Table 79. Thermo Fisher Business Overview
Table 80. Thermo Fisher Cancer Companion Diagnostic Product
Table 81. Thermo Fisher Revenue in Cancer Companion Diagnostic Business (2020-2025) & (US$ Million)
Table 82. Thermo Fisher Recent Development
Table 83. Qiagen Company Details
Table 84. Qiagen Business Overview
Table 85. Qiagen Cancer Companion Diagnostic Product
Table 86. Qiagen Revenue in Cancer Companion Diagnostic Business (2020-2025) & (US$ Million)
Table 87. Qiagen Recent Development
Table 88. Guardant Health Company Details
Table 89. Guardant Health Business Overview
Table 90. Guardant Health Cancer Companion Diagnostic Product
Table 91. Guardant Health Revenue in Cancer Companion Diagnostic Business (2020-2025) & (US$ Million)
Table 92. Guardant Health Recent Development
Table 93. Research Programs/Design for This Report
Table 94. Key Data Information from Secondary Sources
Table 95. Key Data Information from Primary Sources
Table 96. Authors List of This Report
List of Figures
Figure 1. Cancer Companion Diagnostic Picture
Figure 2. Global Cancer Companion Diagnostic Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Cancer Companion Diagnostic Market Share by Type: 2024 VS 2031
Figure 4. Polymerase Chain Reaction (PCR) Features
Figure 5. “Next Generation” Sequencing (NGS) Features
Figure 6. Fluorescence In Situ Hybridization (FISH) Features
Figure 7. Immunohistochemistry (IHC) Features
Figure 8. Global Cancer Companion Diagnostic Market Size by Application (2020-2031) & (US$ Million)
Figure 9. Global Cancer Companion Diagnostic Market Share by Application: 2024 VS 2031
Figure 10. Lung Cancer Case Studies
Figure 11. Colorectal Cancer Case Studies
Figure 12. Breast Cancer Case Studies
Figure 13. Others Case Studies
Figure 14. Cancer Companion Diagnostic Report Years Considered
Figure 15. Global Cancer Companion Diagnostic Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 16. Global Cancer Companion Diagnostic Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 17. Global Cancer Companion Diagnostic Market Share by Region: 2024 VS 2031
Figure 18. Global Cancer Companion Diagnostic Market Share by Players in 2024
Figure 19. Global Top Cancer Companion Diagnostic Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cancer Companion Diagnostic as of 2024)
Figure 20. The Top 10 and 5 Players Market Share by Cancer Companion Diagnostic Revenue in 2024
Figure 21. North America Cancer Companion Diagnostic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. North America Cancer Companion Diagnostic Market Share by Country (2020-2031)
Figure 23. United States Cancer Companion Diagnostic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Canada Cancer Companion Diagnostic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. Europe Cancer Companion Diagnostic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. Europe Cancer Companion Diagnostic Market Share by Country (2020-2031)
Figure 27. Germany Cancer Companion Diagnostic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. France Cancer Companion Diagnostic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. U.K. Cancer Companion Diagnostic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Italy Cancer Companion Diagnostic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Russia Cancer Companion Diagnostic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Nordic Countries Cancer Companion Diagnostic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Asia-Pacific Cancer Companion Diagnostic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Asia-Pacific Cancer Companion Diagnostic Market Share by Region (2020-2031)
Figure 35. China Cancer Companion Diagnostic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Japan Cancer Companion Diagnostic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. South Korea Cancer Companion Diagnostic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Southeast Asia Cancer Companion Diagnostic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. India Cancer Companion Diagnostic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Australia Cancer Companion Diagnostic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Latin America Cancer Companion Diagnostic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Latin America Cancer Companion Diagnostic Market Share by Country (2020-2031)
Figure 43. Mexico Cancer Companion Diagnostic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Brazil Cancer Companion Diagnostic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Middle East & Africa Cancer Companion Diagnostic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Middle East & Africa Cancer Companion Diagnostic Market Share by Country (2020-2031)
Figure 47. Turkey Cancer Companion Diagnostic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. Saudi Arabia Cancer Companion Diagnostic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. UAE Cancer Companion Diagnostic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 50. AmoyDx Revenue Growth Rate in Cancer Companion Diagnostic Business (2020-2025)
Figure 51. Novogene Revenue Growth Rate in Cancer Companion Diagnostic Business (2020-2025)
Figure 52. Illumina Revenue Growth Rate in Cancer Companion Diagnostic Business (2020-2025)
Figure 53. Roche Revenue Growth Rate in Cancer Companion Diagnostic Business (2020-2025)
Figure 54. Agilent Revenue Growth Rate in Cancer Companion Diagnostic Business (2020-2025)
Figure 55. Abbott Revenue Growth Rate in Cancer Companion Diagnostic Business (2020-2025)
Figure 56. Thermo Fisher Revenue Growth Rate in Cancer Companion Diagnostic Business (2020-2025)
Figure 57. Qiagen Revenue Growth Rate in Cancer Companion Diagnostic Business (2020-2025)
Figure 58. Guardant Health Revenue Growth Rate in Cancer Companion Diagnostic Business (2020-2025)
Figure 59. Bottom-up and Top-down Approaches for This Report
Figure 60. Data Triangulation
Figure 61. Key Executives Interviewed
Table 1. Global Cancer Companion Diagnostic Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Polymerase Chain Reaction (PCR)
Table 3. Key Players of “Next Generation” Sequencing (NGS)
Table 4. Key Players of Fluorescence In Situ Hybridization (FISH)
Table 5. Key Players of Immunohistochemistry (IHC)
Table 6. Global Cancer Companion Diagnostic Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 7. Global Cancer Companion Diagnostic Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 8. Global Cancer Companion Diagnostic Market Size by Region (2020-2025) & (US$ Million)
Table 9. Global Cancer Companion Diagnostic Market Share by Region (2020-2025)
Table 10. Global Cancer Companion Diagnostic Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 11. Global Cancer Companion Diagnostic Market Share by Region (2026-2031)
Table 12. Cancer Companion Diagnostic Market Trends
Table 13. Cancer Companion Diagnostic Market Drivers
Table 14. Cancer Companion Diagnostic Market Challenges
Table 15. Cancer Companion Diagnostic Market Restraints
Table 16. Global Cancer Companion Diagnostic Revenue by Players (2020-2025) & (US$ Million)
Table 17. Global Cancer Companion Diagnostic Market Share by Players (2020-2025)
Table 18. Global Top Cancer Companion Diagnostic Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cancer Companion Diagnostic as of 2024)
Table 19. Ranking of Global Top Cancer Companion Diagnostic Companies by Revenue (US$ Million) in 2024
Table 20. Global 5 Largest Players Market Share by Cancer Companion Diagnostic Revenue (CR5 and HHI) & (2020-2025)
Table 21. Global Key Players of Cancer Companion Diagnostic, Headquarters and Area Served
Table 22. Global Key Players of Cancer Companion Diagnostic, Product and Application
Table 23. Global Key Players of Cancer Companion Diagnostic, Date of Enter into This Industry
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Cancer Companion Diagnostic Market Size by Type (2020-2025) & (US$ Million)
Table 26. Global Cancer Companion Diagnostic Revenue Market Share by Type (2020-2025)
Table 27. Global Cancer Companion Diagnostic Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 28. Global Cancer Companion Diagnostic Revenue Market Share by Type (2026-2031)
Table 29. Global Cancer Companion Diagnostic Market Size by Application (2020-2025) & (US$ Million)
Table 30. Global Cancer Companion Diagnostic Revenue Market Share by Application (2020-2025)
Table 31. Global Cancer Companion Diagnostic Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 32. Global Cancer Companion Diagnostic Revenue Market Share by Application (2026-2031)
Table 33. North America Cancer Companion Diagnostic Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 34. North America Cancer Companion Diagnostic Market Size by Country (2020-2025) & (US$ Million)
Table 35. North America Cancer Companion Diagnostic Market Size by Country (2026-2031) & (US$ Million)
Table 36. Europe Cancer Companion Diagnostic Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 37. Europe Cancer Companion Diagnostic Market Size by Country (2020-2025) & (US$ Million)
Table 38. Europe Cancer Companion Diagnostic Market Size by Country (2026-2031) & (US$ Million)
Table 39. Asia-Pacific Cancer Companion Diagnostic Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 40. Asia-Pacific Cancer Companion Diagnostic Market Size by Region (2020-2025) & (US$ Million)
Table 41. Asia-Pacific Cancer Companion Diagnostic Market Size by Region (2026-2031) & (US$ Million)
Table 42. Latin America Cancer Companion Diagnostic Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 43. Latin America Cancer Companion Diagnostic Market Size by Country (2020-2025) & (US$ Million)
Table 44. Latin America Cancer Companion Diagnostic Market Size by Country (2026-2031) & (US$ Million)
Table 45. Middle East & Africa Cancer Companion Diagnostic Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 46. Middle East & Africa Cancer Companion Diagnostic Market Size by Country (2020-2025) & (US$ Million)
Table 47. Middle East & Africa Cancer Companion Diagnostic Market Size by Country (2026-2031) & (US$ Million)
Table 48. AmoyDx Company Details
Table 49. AmoyDx Business Overview
Table 50. AmoyDx Cancer Companion Diagnostic Product
Table 51. AmoyDx Revenue in Cancer Companion Diagnostic Business (2020-2025) & (US$ Million)
Table 52. AmoyDx Recent Development
Table 53. Novogene Company Details
Table 54. Novogene Business Overview
Table 55. Novogene Cancer Companion Diagnostic Product
Table 56. Novogene Revenue in Cancer Companion Diagnostic Business (2020-2025) & (US$ Million)
Table 57. Novogene Recent Development
Table 58. Illumina Company Details
Table 59. Illumina Business Overview
Table 60. Illumina Cancer Companion Diagnostic Product
Table 61. Illumina Revenue in Cancer Companion Diagnostic Business (2020-2025) & (US$ Million)
Table 62. Illumina Recent Development
Table 63. Roche Company Details
Table 64. Roche Business Overview
Table 65. Roche Cancer Companion Diagnostic Product
Table 66. Roche Revenue in Cancer Companion Diagnostic Business (2020-2025) & (US$ Million)
Table 67. Roche Recent Development
Table 68. Agilent Company Details
Table 69. Agilent Business Overview
Table 70. Agilent Cancer Companion Diagnostic Product
Table 71. Agilent Revenue in Cancer Companion Diagnostic Business (2020-2025) & (US$ Million)
Table 72. Agilent Recent Development
Table 73. Abbott Company Details
Table 74. Abbott Business Overview
Table 75. Abbott Cancer Companion Diagnostic Product
Table 76. Abbott Revenue in Cancer Companion Diagnostic Business (2020-2025) & (US$ Million)
Table 77. Abbott Recent Development
Table 78. Thermo Fisher Company Details
Table 79. Thermo Fisher Business Overview
Table 80. Thermo Fisher Cancer Companion Diagnostic Product
Table 81. Thermo Fisher Revenue in Cancer Companion Diagnostic Business (2020-2025) & (US$ Million)
Table 82. Thermo Fisher Recent Development
Table 83. Qiagen Company Details
Table 84. Qiagen Business Overview
Table 85. Qiagen Cancer Companion Diagnostic Product
Table 86. Qiagen Revenue in Cancer Companion Diagnostic Business (2020-2025) & (US$ Million)
Table 87. Qiagen Recent Development
Table 88. Guardant Health Company Details
Table 89. Guardant Health Business Overview
Table 90. Guardant Health Cancer Companion Diagnostic Product
Table 91. Guardant Health Revenue in Cancer Companion Diagnostic Business (2020-2025) & (US$ Million)
Table 92. Guardant Health Recent Development
Table 93. Research Programs/Design for This Report
Table 94. Key Data Information from Secondary Sources
Table 95. Key Data Information from Primary Sources
Table 96. Authors List of This Report
List of Figures
Figure 1. Cancer Companion Diagnostic Picture
Figure 2. Global Cancer Companion Diagnostic Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Cancer Companion Diagnostic Market Share by Type: 2024 VS 2031
Figure 4. Polymerase Chain Reaction (PCR) Features
Figure 5. “Next Generation” Sequencing (NGS) Features
Figure 6. Fluorescence In Situ Hybridization (FISH) Features
Figure 7. Immunohistochemistry (IHC) Features
Figure 8. Global Cancer Companion Diagnostic Market Size by Application (2020-2031) & (US$ Million)
Figure 9. Global Cancer Companion Diagnostic Market Share by Application: 2024 VS 2031
Figure 10. Lung Cancer Case Studies
Figure 11. Colorectal Cancer Case Studies
Figure 12. Breast Cancer Case Studies
Figure 13. Others Case Studies
Figure 14. Cancer Companion Diagnostic Report Years Considered
Figure 15. Global Cancer Companion Diagnostic Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 16. Global Cancer Companion Diagnostic Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 17. Global Cancer Companion Diagnostic Market Share by Region: 2024 VS 2031
Figure 18. Global Cancer Companion Diagnostic Market Share by Players in 2024
Figure 19. Global Top Cancer Companion Diagnostic Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cancer Companion Diagnostic as of 2024)
Figure 20. The Top 10 and 5 Players Market Share by Cancer Companion Diagnostic Revenue in 2024
Figure 21. North America Cancer Companion Diagnostic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. North America Cancer Companion Diagnostic Market Share by Country (2020-2031)
Figure 23. United States Cancer Companion Diagnostic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Canada Cancer Companion Diagnostic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. Europe Cancer Companion Diagnostic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. Europe Cancer Companion Diagnostic Market Share by Country (2020-2031)
Figure 27. Germany Cancer Companion Diagnostic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. France Cancer Companion Diagnostic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. U.K. Cancer Companion Diagnostic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Italy Cancer Companion Diagnostic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Russia Cancer Companion Diagnostic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Nordic Countries Cancer Companion Diagnostic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Asia-Pacific Cancer Companion Diagnostic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Asia-Pacific Cancer Companion Diagnostic Market Share by Region (2020-2031)
Figure 35. China Cancer Companion Diagnostic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Japan Cancer Companion Diagnostic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. South Korea Cancer Companion Diagnostic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Southeast Asia Cancer Companion Diagnostic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. India Cancer Companion Diagnostic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Australia Cancer Companion Diagnostic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Latin America Cancer Companion Diagnostic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Latin America Cancer Companion Diagnostic Market Share by Country (2020-2031)
Figure 43. Mexico Cancer Companion Diagnostic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Brazil Cancer Companion Diagnostic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Middle East & Africa Cancer Companion Diagnostic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Middle East & Africa Cancer Companion Diagnostic Market Share by Country (2020-2031)
Figure 47. Turkey Cancer Companion Diagnostic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. Saudi Arabia Cancer Companion Diagnostic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. UAE Cancer Companion Diagnostic Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 50. AmoyDx Revenue Growth Rate in Cancer Companion Diagnostic Business (2020-2025)
Figure 51. Novogene Revenue Growth Rate in Cancer Companion Diagnostic Business (2020-2025)
Figure 52. Illumina Revenue Growth Rate in Cancer Companion Diagnostic Business (2020-2025)
Figure 53. Roche Revenue Growth Rate in Cancer Companion Diagnostic Business (2020-2025)
Figure 54. Agilent Revenue Growth Rate in Cancer Companion Diagnostic Business (2020-2025)
Figure 55. Abbott Revenue Growth Rate in Cancer Companion Diagnostic Business (2020-2025)
Figure 56. Thermo Fisher Revenue Growth Rate in Cancer Companion Diagnostic Business (2020-2025)
Figure 57. Qiagen Revenue Growth Rate in Cancer Companion Diagnostic Business (2020-2025)
Figure 58. Guardant Health Revenue Growth Rate in Cancer Companion Diagnostic Business (2020-2025)
Figure 59. Bottom-up and Top-down Approaches for This Report
Figure 60. Data Triangulation
Figure 61. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Potassium Bromide Windows Market Research Report 2025
Dec 14, 25
Global Bio-based 1,10-Decanediol Diacrylate Market Research Report 2025
Dec 14, 25
Global Bio-based 1,5-Pentanediol Diacrylate(PDDA) Market Research Report 2025
Dec 14, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232